Two-hybrid usage

Back to the introduction page

See a list of articles using any kind of two-hybrid system (published till October 1995)

Art. N	prot. 1	prot 2	bait type	prey type	Lib. screen or	system type
					def. set testing
					(c, control)

1	.	.	splicing	splicing	.	e
1	period	.	o	.	c	.
8	Nef	beta-COP	o	ves.tr	l	g2
8	.	.	.	? (2)	.	.
10	cycB	CAML	cyclophilin	Ca	l	.
10	cycA	beta-tubulin	cyclophilin	.	.	.
11	Rab3A	Rabin	g	.	l	g2
12	PET54, PET122, PET494	PET54, PET122, PET494	transl.a	transl.a	s (3) pairw	g
13	RBP3 (domain)	prot H	dbp	dbp	l	g
15	Vav(C-term)	hnRNP K	signaling	.	l	g
15	Ras	Raf	g	pk	c	g
15	Grb2	sos	a	gef	c	g
16	ras1	byr2	g	pk	l,c	Xg
16	ras1	scd1	g	.	l,s	Xg
16	cdc42sp	scd1, scd2	G	.	s	Xg
16	scd2	scd1	.	.	s	Xg
18	Cap1 delta	Cap1 AID	pp	pp	s	o (Ace1 based)
18	Cap1 delta	Cmd1	pp	Ca	s	o (Ace1 based)
19	Bruton's ptk	Fyn	pk	pk	l	e
22	ANP-receptor kinase-like	novel	pp	pk	l	xv
23	FKBP-rapamycin	RAPT1	.	.	l	xv
24a	Ste5	Ste11, Ste7, Fus3, Kss1	o	pk	s	e
25	Ste4	Ste18	G-p	G-p	s	g
28	Not1	Not2, 4	tr	tr	s	e
28	Not3	Not1, 4	tr	tr	s	e
29	RAG1	SRP1	rec	o	l	e
33	Rad51	Rad51	rep	rep	s	g
33	Rad51	Rad52	rep	rep	s	g
34	Rb	CycD1	Rb	cyclin	c	g
34	Rb	BRG1	Rb	tr	l, s	g, Xg
35	p110RB	PP-1 alpha 2	Rb	pp	l	g
35	p110RB	T-antigen SV-40	Rb	pp	l	g
36	p110RB(N-term)	p84	Rb	nuc. matrix?	l	g
36a	Far1	Fus3	o	Zn finger	s	e
38	E4 ORF6/7	E2F-1	adenov	tr.f	s	o (SRF dbd)V, mamm. g
39	Raf-1	HS1	pk	14-3-3	l	g2
39	Raf-1	PLA2	pk	14-3-3	l	g2
39	Raf-1	?	pk	.	l	g2
40	TFB1	SSL1	tr.f	rep	l	g2
40	TFB1	?(2)	tr.f	.	l	g2
42	Bcl-2	R-Ras	apopt	g	l	g2
42	Bcl-2	?	apopt		l	g2
46	HsCdc2, HsCdk2	Cdi2	cdk	o	s	e
46	DmCdc2c, ScCdc28	Cdi3, 5	cdk	cyclin	s	e
46	DmCdc2	Cdi3, 7	cdk	cyclin	s	e
46	HsCdk3, 4	Cdi3	cdk	cyclin	s	e
46	DmCdc2, ScCdc28	Cdi2	cdk	o	s	e
46	DmCdc2c, HsCdk3	Cdi2, 4	cdk	o	s	e
46	cdi11	Cdi3	o	cyclin	s	e
46	cdi11	Cdi4	o	o	s	e
46	Cdi5	Cdi2	cyclin	o	s	e
52	Calmodulin	Spc110	Ca	o	s, l	g
54	B (N-term)	C1	tr.f.	tr	s	gv
55	Cdk6	p16	cdk	o	l	g2
55		p18
58	p52shc	PTP-PEST	pk	pp	s	g
60	Cdk2	Rbr-2	cdk	Rb	l	g2
60		cks1		o
60				?
61	RAP1	RIF	tr	o	l	g
64	p110RB	p110RB	Rb	Rb	s	g
65	PHO2	PHO4	cdk	ta	s	Xv
67	Ras	RalGDS	g	gd	l	g
68	.	.	ab	ag	s	g
69	PI3-kin. subunit P110	PI3-kin. subunit P85	pk	pk	s	g
73	SNF1	MSN3 (STD1)	pk	o	l	g
76	p53	p53	p53	p53	l	g
77	cdc7	DBF4	pk	cyclin-like	s	Xg
78	PHO80	PHO4	tr	tr	s	Xv
80	Max	Myc	dbp	dbp	s	gv
84	ras p21	RGL, for ralGDS-like	g	gd	l	g
85	CENP-B	CENP-B	dbp	dbp	s	Xg
86	Fus3	Ste5	pk	.	.	e
87	Cdc23p	Cdc27p	cdc	cdc	s	g
90	protX	XAP-1	tta	rep	l	g
91	SPP91 and PRP11	.	spl	spl	s	.
92	SPP91 and PRP11	.	spl	spl	s	g
96	Raf-1	14-3-3	pk	o	l	g2
99	Pr55gag	Pr55gag	gag	gag	.	g
99	M-MuLV	M-MuLV	gag	gag	.	g
102	MO15	cyclinH	pk	cyclin	l	e
102	MO15	?	pk	.	l	e
103	GCN5	ADA2	t.ad	t.ad	s	Xv
104	STE5 , STE11, STE7, FUS3		pheromone-resp 12x12		s	Xg
107	IL-2 rec	.	recep	o	l	g
108	mPPAR and hRXR (bothways)		recep	recep	s	g
110	ras	cdc25	g	gef	s	g
111a	Ras2	CDC25	g	cdc	s	o
111a	BCY1	.	o - dimeriz	.	c	.
115	insulin receptor	IRS-1	recep	o	s	e
116	HRH1	SR prot fam	spl	dbp	s	g
118	Rad7	SIR3	rep	dbp	s	g
118	.	2 novel	.	.	.	.
123	c-abl domain	Crk	pk	a	l	e
123	.	novel	.	?	.	.
123	.	novel	.	?	.	.
125	SH3 domain of Fyn	p62	pk(SH3)	a	l	g
126	TNFR2	TRAF1, TRAF2	recep	o	l	g2
126	TRAF2	TRAF1, TRAF2	o	o	s	g2
127	hTAF	hTBP	tr.f	tr.f	s	g
132	CDK4	p16ink4	cdk	o	l	g
133	HSF2	HSF2	tr.f (HSF2)	tr	s	X
135	TNFR-1 domains	TNFR-1 domains	recep	recep	s, l	g2
136	TNFR-1IC	TRAP-1	recep	hsp	l	.
137	R-ras	RalGDS	g	gds	l	g2
137	H,Kras Rap	RalGDS	g(3)	gds	s
138	Ras	Raf	g	pk	s	g
139	FKBP12-rapamycin	TOR2	o	o	s	g
140	E12	Id-2	tr.f	tr.f	s	g
140	E12	MyoD	tr.f	.	c	.
141	Calmodulin	Spc110p	Ca	o	l	g
141	Calmodulin	4 known Ca-binding*	Ca	o(4)	.	.
141	Calmodulin	transcription factor	Ca	tr	.	.
142	PKC	PICK1	pk	.	.	g
145	cyclinD1	p27	cyclin	inhibitor?	.	gV
146	EBNA-2	EBNA-2	viral nucl		s	Xg
146	SIR4	SIR4	.	.	c	.
148	TGF-beta R-I	TGF-betaR-II	recep	recep	s	e
152	SC35	SC35	spl	spl	l,s	e
152	SC35	U2AF35	spl	spl	l,s	e
152	SC35	U1-70K	spl	spl	l,s	e
152	SC35	SF2/ASF	spl	spl	s	e
152	SC35	U2AF65	spl	spl	s	e
152	SC35	SF2/ASF, U1-70K	spl	spl	s	e
152	SC35	Tra, Tra-2	spl	spl	s	e
152	U2AF35	SC35,SF2/ASF, U2AF35/65, Tra, Tra-2	spl	spl	s	e
152	SF2/ASF	SC35,SF2/ASF, U2AF35, U1-70K	spl	spl	s	e
153	Insulin receptor	LIM containing prot	recep	?	l	e
157	SNF1	SIP1	pk	o	l	.
158	SNF1	SIP1	pk	a?	l	Xg
158	SNF1	SIP2,3,4	pk	?	.	.
160	Vav	GRB	st (vav)	a	l	e
160	Vav	pro-rich	.	?	l	e
160	Vav	.	.	? (3)	l	e
161	Dr1	TBP	tr	.	s	e+g
163	Raf	Ras	pk	g	s	g
163	Raf	Rap1	pk	g	s	g
164	Myo	E12, E47	tr	tr	s	gV
165	3 hepadnavirus C-prot	3 hepadnavirus C-prot	o	o	s	gV
166	Fos	Jun	tr.f	tr.f	c	.
173	RBTN1, RBTN2 (LIM)	TAL1, TAL2 and LYL1	tr.f	tr.f	s	gV (modif)

Abbreviations for classifications of interacting proteins are: a, adaptor protein; ab, antibody; ag, antigen; apopt, apoptosis-related protein; ca, calcium regulated protein; cdc, cell division control; cdk, cyclin dependent kinase; cyp, cyclophilin protein; dbp, DNA-binding protein; g, GTPase; g-p, G-protein; gds, GDP-dissociation stimulator; gef, GTP-GDP exchange factor; o, other; pk, protein kinase; pp, protein phosphatase; rec, recombination protein; recep, receptor protein; rep, DNA repair factor; spl, splicing factor; st, signal transduction related; t. ad., transcription adaptor; tr, transcriptional regulator; tr. f., transcription factor; transl.a., translational activator; tta, transcription transactivator.

Abbreviations for method in which interaction was detected are: s, predefined set of proteins; l, library screen, c, control.

Abbreviations for two-hybrid system are: g and g2: gal4 based systems (lacZ only and his3 + lacZ used, respectively); e: LexA BD, "Acid blob" AD; GV: Gal4 BD, VP16 AD; XV: lexA BD, VP16 AD; Xg: lexA BD, Gal4 AD (AD, BD: activation and DNA binding domains, respectively)

Back to the introduction page

See a list of articles using any kind of two-hybrid system (published till October 1995)